

Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/G958F97C8C5FEN.html>

Date: July 2024

Pages: 83

Price: US\$ 3,480.00 (Single User License)

ID: G958F97C8C5FEN

Abstracts

According to our (Global Info Research) latest study, the global Non-Alcoholic Steatohepatitis (NASH) Treatment market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Non-Alcoholic Steatohepatitis (NASH) Treatment industry chain, the market status of Hospital Pharmacy (Off-Label, Therapeutic), Online Provider (Off-Label, Therapeutic), and key enterprises in developed and developing market, and analysed the cutting-

edge technology, patent, hot applications and market trends of Non-Alcoholic Steatohepatitis (NASH) Treatment.

Regionally, the report analyzes the Non-Alcoholic Steatohepatitis (NASH) Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Non-Alcoholic Steatohepatitis (NASH) Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Non-Alcoholic Steatohepatitis (NASH) Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Non-Alcoholic Steatohepatitis (NASH) Treatment industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Off-Label, Therapeutic).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Non-Alcoholic Steatohepatitis (NASH) Treatment market.

Regional Analysis: The report involves examining the Non-Alcoholic Steatohepatitis (NASH) Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Non-Alcoholic Steatohepatitis (NASH) Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Non-Alcoholic Steatohepatitis (NASH) Treatment:

Company Analysis: Report covers individual Non-Alcoholic Steatohepatitis (NASH) Treatment players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Non-Alcoholic Steatohepatitis (NASH) Treatment. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacy, Online Provider).

Technology Analysis: Report covers specific technologies relevant to Non-Alcoholic Steatohepatitis (NASH) Treatment. It assesses the current state, advancements, and potential future developments in Non-Alcoholic Steatohepatitis (NASH) Treatment areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Non-Alcoholic Steatohepatitis (NASH) Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Non-Alcoholic Steatohepatitis (NASH) Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type

Off-Label

Therapeutic

Market segment by Application

Hospital Pharmacy

Online Provider

Retail Pharmacy

Market segment by players, this report covers

Allergan Plc (Tobira)

Bristol Myers Squibb

Galmed Pharmaceuticals

Genfit SA

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Zydus Cadila

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Non-Alcoholic Steatohepatitis (NASH) Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Non-Alcoholic Steatohepatitis (NASH) Treatment, with revenue, gross margin and global market share of Non-Alcoholic Steatohepatitis (NASH) Treatment from 2019 to 2024.

Chapter 3, the Non-Alcoholic Steatohepatitis (NASH) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024. and Non-Alcoholic Steatohepatitis (NASH) Treatment market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Alcoholic Steatohepatitis (NASH) Treatment.

Chapter 13, to describe Non-Alcoholic Steatohepatitis (NASH) Treatment research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Non-Alcoholic Steatohepatitis (NASH) Treatment

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Non-Alcoholic Steatohepatitis (NASH) Treatment by Type

1.3.1 Overview: Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type: 2019 Versus 2023 Versus 2030

1.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type in 2023

1.3.3 Off-Label

1.3.4 Therapeutic

1.4 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market by Application

1.4.1 Overview: Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application: 2019 Versus 2023 Versus 2030

1.4.2 Hospital Pharmacy

1.4.3 Online Provider

1.4.4 Retail Pharmacy

1.5 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size & Forecast

1.6 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast by Region

1.6.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region: 2019 VS 2023 VS 2030

1.6.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region, (2019-2030)

1.6.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Prospect (2019-2030)

1.6.4 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Prospect (2019-2030)

1.6.5 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Prospect (2019-2030)

1.6.6 South America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Prospect (2019-2030)

1.6.7 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Prospect (2019-2030)

2 COMPANY PROFILES

2.1 Allergan Plc (Tobira)

2.1.1 Allergan Plc (Tobira) Details

2.1.2 Allergan Plc (Tobira) Major Business

2.1.3 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

2.1.4 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Allergan Plc (Tobira) Recent Developments and Future Plans

2.2 Bristol Myers Squibb

2.2.1 Bristol Myers Squibb Details

2.2.2 Bristol Myers Squibb Major Business

2.2.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

2.2.4 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.2.5 Bristol Myers Squibb Recent Developments and Future Plans

2.3 Galmed Pharmaceuticals

2.3.1 Galmed Pharmaceuticals Details

2.3.2 Galmed Pharmaceuticals Major Business

2.3.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

2.3.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.3.5 Galmed Pharmaceuticals Recent Developments and Future Plans

2.4 Genfit SA

2.4.1 Genfit SA Details

2.4.2 Genfit SA Major Business

2.4.3 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

2.4.4 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)

2.4.5 Genfit SA Recent Developments and Future Plans

2.5 Gilead Sciences, Inc.

2.5.1 Gilead Sciences, Inc. Details

2.5.2 Gilead Sciences, Inc. Major Business

2.5.3 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

2.5.4 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)

- 2.5.5 Gilead Sciences, Inc. Recent Developments and Future Plans
- 2.6 Intercept Pharmaceuticals, Inc.
 - 2.6.1 Intercept Pharmaceuticals, Inc. Details
 - 2.6.2 Intercept Pharmaceuticals, Inc. Major Business
 - 2.6.3 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions
 - 2.6.4 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)
 - 2.6.5 Intercept Pharmaceuticals, Inc. Recent Developments and Future Plans
- 2.7 Zydus Cadila
 - 2.7.1 Zydus Cadila Details
 - 2.7.2 Zydus Cadila Major Business
 - 2.7.3 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions
 - 2.7.4 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, Gross Margin and Market Share (2019-2024)
 - 2.7.5 Zydus Cadila Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
 - 3.2.1 Market Share of Non-Alcoholic Steatohepatitis (NASH) Treatment by Company Revenue
 - 3.2.2 Top 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Players Market Share in 2023
 - 3.2.3 Top 6 Non-Alcoholic Steatohepatitis (NASH) Treatment Players Market Share in 2023
- 3.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Overall Company Footprint Analysis
 - 3.3.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Region Footprint
 - 3.3.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Company Product Type Footprint
 - 3.3.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value and Market Share by Type (2019-2024)

4.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Forecast by Type (2025-2030)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application (2019-2024)

5.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Forecast by Application (2025-2030)

6 NORTH AMERICA

6.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2030)

6.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2030)

6.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country

6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2030)

6.3.2 United States Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

7 EUROPE

7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2030)

7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2030)

7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country

7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by

Country (2019-2030)

7.3.2 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

7.3.3 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

7.3.4 United Kingdom Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

7.3.5 Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

7.3.6 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

8 ASIA-PACIFIC

8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2030)

8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2030)

8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region

8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Region (2019-2030)

8.3.2 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

8.3.3 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

8.3.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

8.3.5 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

8.3.6 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

8.3.7 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

9 SOUTH AMERICA

9.1 South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2030)

9.2 South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2030)

9.3 South America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country

9.3.1 South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2030)

9.3.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

9.3.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2030)

10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2030)

10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country

10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2030)

10.3.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

10.3.3 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

10.3.4 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size and Forecast (2019-2030)

11 MARKET DYNAMICS

11.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers

11.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints

11.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Chain
- 12.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Upstream Analysis
- 12.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Midstream Analysis
- 12.4 Non-Alcoholic Steatohepatitis (NASH) Treatment Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Region (2019-2024) & (USD Million)

Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Region (2025-2030) & (USD Million)

Table 5. Allergan Plc (Tobira) Company Information, Head Office, and Major Competitors

Table 6. Allergan Plc (Tobira) Major Business

Table 7. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

Table 8. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 9. Allergan Plc (Tobira) Recent Developments and Future Plans

Table 10. Bristol Myers Squibb Company Information, Head Office, and Major Competitors

Table 11. Bristol Myers Squibb Major Business

Table 12. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

Table 13. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 14. Bristol Myers Squibb Recent Developments and Future Plans

Table 15. Galmed Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 16. Galmed Pharmaceuticals Major Business

Table 17. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

Table 18. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 19. Galmed Pharmaceuticals Recent Developments and Future Plans

Table 20. Genfit SA Company Information, Head Office, and Major Competitors

Table 21. Genfit SA Major Business

Table 22. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product and

Solutions

Table 23. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 24. Genfit SA Recent Developments and Future Plans

Table 25. Gilead Sciences, Inc. Company Information, Head Office, and Major Competitors

Table 26. Gilead Sciences, Inc. Major Business

Table 27. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

Table 28. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 29. Gilead Sciences, Inc. Recent Developments and Future Plans

Table 30. Intercept Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors

Table 31. Intercept Pharmaceuticals, Inc. Major Business

Table 32. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

Table 33. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 34. Intercept Pharmaceuticals, Inc. Recent Developments and Future Plans

Table 35. Zydus Cadila Company Information, Head Office, and Major Competitors

Table 36. Zydus Cadila Major Business

Table 37. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product and Solutions

Table 38. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 39. Zydus Cadila Recent Developments and Future Plans

Table 40. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (USD Million) by Players (2019-2024)

Table 41. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Players (2019-2024)

Table 42. Breakdown of Non-Alcoholic Steatohepatitis (NASH) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)

Table 43. Market Position of Players in Non-Alcoholic Steatohepatitis (NASH) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023

Table 44. Head Office of Key Non-Alcoholic Steatohepatitis (NASH) Treatment Players

Table 45. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Company Product Type Footprint

Table 46. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Company Product

Application Footprint

Table 47. Non-Alcoholic Steatohepatitis (NASH) Treatment New Market Entrants and Barriers to Market Entry

Table 48. Non-Alcoholic Steatohepatitis (NASH) Treatment Mergers, Acquisition, Agreements, and Collaborations

Table 49. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (USD Million) by Type (2019-2024)

Table 50. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Share by Type (2019-2024)

Table 51. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Forecast by Type (2025-2030)

Table 52. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2024)

Table 53. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Forecast by Application (2025-2030)

Table 54. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 55. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 56. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 57. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 58. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 59. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 60. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 61. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 62. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 63. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 64. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 65. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 66. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 67. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 68. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 69. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 70. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Region (2019-2024) & (USD Million)

Table 71. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Region (2025-2030) & (USD Million)

Table 72. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 73. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 74. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 75. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 76. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 77. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 78. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2019-2024) & (USD Million)

Table 79. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type (2025-2030) & (USD Million)

Table 80. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2019-2024) & (USD Million)

Table 81. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Application (2025-2030) & (USD Million)

Table 82. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2019-2024) & (USD Million)

Table 83. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Country (2025-2030) & (USD Million)

Table 84. Non-Alcoholic Steatohepatitis (NASH) Treatment Raw Material

Table 85. Key Suppliers of Non-Alcoholic Steatohepatitis (NASH) Treatment Raw Materials

List Of Figures

LIST OF FIGURES

- Figure 1. Non-Alcoholic Steatohepatitis (NASH) Treatment Picture
- Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type in 2023
- Figure 4. Off-Label
- Figure 5. Therapeutic
- Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 7. Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application in 2023
- Figure 8. Hospital Pharmacy Picture
- Figure 9. Online Provider Picture
- Figure 10. Retail Pharmacy Picture
- Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value, (USD Million): 2019 & 2023 & 2030
- Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value and Forecast (2019-2030) & (USD Million)
- Figure 13. Global Market Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
- Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Region (2019-2030)
- Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Region in 2023
- Figure 16. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 17. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 18. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 19. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 20. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)
- Figure 21. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by

Players in 2023

Figure 22. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023

Figure 23. Global Top 3 Players Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share in 2023

Figure 24. Global Top 6 Players Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share in 2023

Figure 25. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Share by Type (2019-2024)

Figure 26. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share Forecast by Type (2025-2030)

Figure 27. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Share by Application (2019-2024)

Figure 28. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share Forecast by Application (2025-2030)

Figure 29. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type (2019-2030)

Figure 30. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application (2019-2030)

Figure 31. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Country (2019-2030)

Figure 32. United States Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 33. Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 34. Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type (2019-2030)

Figure 36. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application (2019-2030)

Figure 37. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Country (2019-2030)

Figure 38. Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 39. France Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 40. United Kingdom Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 41. Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 42. Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 43. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type (2019-2030)

Figure 44. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application (2019-2030)

Figure 45. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Region (2019-2030)

Figure 46. China Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 47. Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 48. South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 49. India Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 50. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 51. Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 52. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type (2019-2030)

Figure 53. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application (2019-2030)

Figure 54. South America Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Country (2019-2030)

Figure 55. Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 56. Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 57. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Type (2019-2030)

Figure 58. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Application (2019-2030)

Figure 59. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value Market Share by Country (2019-2030)

Figure 60. Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value

(2019-2030) & (USD Million)

Figure 61. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 62. UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Consumption Value (2019-2030) & (USD Million)

Figure 63. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers

Figure 64. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints

Figure 65. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends

Figure 66. Porters Five Forces Analysis

Figure 67. Manufacturing Cost Structure Analysis of Non-Alcoholic Steatohepatitis (NASH) Treatment in 2023

Figure 68. Manufacturing Process Analysis of Non-Alcoholic Steatohepatitis (NASH) Treatment

Figure 69. Non-Alcoholic Steatohepatitis (NASH) Treatment Industrial Chain

Figure 70. Methodology

Figure 71. Research Process and Data Source

I would like to order

Product name: Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/G958F97C8C5FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G958F97C8C5FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

